Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1240084 | 0.97 | TSHR (0.42) | TSHRMAPTABCC4ALDH1A1USP2 | |
| SCHEMBL3996665 | 0.92 | TSHR (0.39) | TSHRMAPTABCC4ALDH1A1USP2 | |
| SCHEMBL3241664 | 0.91 | TSHR (0.39) | TSHRMAPTABCC4ALDH1A1USP2 | |
| SCHEMBL3242623 | 0.91 | TSHR (0.39) | TSHRMAPTABCC4ALDH1A1USP2 | |
| SCHEMBL3232533 | 0.91 | TSHR (0.39) | TSHRMAPTABCC4ALDH1A1USP2 | |
| SCHEMBL1242583 | 0.89 | TSHR (0.41) | TSHRMAPTABCC4ALDH1A1TRPA1 | |
| SCHEMBL9979412 | 0.89 | TSHR (0.67) | TSHRALDH1A1S1PR2S1PR1S1PR3 | |
| SCHEMBL3666728 | 0.89 | TSHR (0.54) | TSHRMAPTABCC4ALDH1A1USP2 | |
| SCHEMBL31035758 | 0.89 | TSHR (0.67) | TSHRALDH1A1S1PR2S1PR1S1PR3 | |
| SCHEMBL8430095 | 0.89 | TSHR (0.67) | TSHRALDH1A1S1PR2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023145372-A1 | METHOD FOR PRODUCING AMIDE COMPOUND | 日本曹達株式会社 | 2023-08-03 | — | — | WO | disclosed |
| US-9201010-B2 | Fluorescent organic nanoparticles | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2015-12-01 | — | — | US | disclosed |
| US-20090272913-A1 | FLUORESCENT ORGANIC NANOPARTICLES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090272913-A1 | FLUORESCENT ORGANIC NANOPARTICLES | LIPA, HCN1, PORCN | TSHR 1966/4885MAPT 407/4885ABCC4 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.